ELIGARD® provides effective testosterone suppression across all dosages2 • Mean serum testosterone levels are consistently below castrate and optimal control levels across all ELIGARD® dosages2 Mean serum testosterone levels2 700 600 500 400 300 200 100 80 60 40 20 0 Serum testosterone concentration (ng/dL) Testosterone castration level (50 ng/dL) Optimal control of testosterone (20 ng/dL) 0 28 58 112 140 168 Days Adapted from Schulman C, et al; 20072 196 224 252 280 308 336 84 22.5 mg ELIGARD® (3-month) 45 mg ELIGARD® (6-month) Evidence shows that lowering testosterone levels < 20 ng/dL improves patient survival and delays disease progression3 Offers the convenience of 6-monthly injections in patients with advanced prostate cancer1 MONTHLY 6 Adapted from Crawford ED, et al; 20183 ADT: androgen deprivation therapy Proportion of patients achieving testosterone suppression3 ADT therapy Testosterone ≤ 50 ng/dL Testosterone ≤ 20 ng/dL Subcutaneous leuprolide acetate 94 – 99 90 – 96 ELIGARD® achieves normal serum PSA levels in 93 % - 96 % of patients2 Adapted from Schulman C, et al; 20072 *based on testosterone responders EAU: European Association of Urology; ADSC-LA: ATRIGEL® polymer-delivered subcutaneous leuprolide acetate Comparative effects of ELIGARD® on PSA levels in clinical studies2 ELIGARD 22.5 mg (3-month) ELIGARD 45 mg (6-month) % patients with normal PSA at baseline (< 4 ng/mL) 27 % 25 % % patients with normal PSA at study end (< 4 ng/mL) 93 %* 96 % For full prescribing information refer to the Professional Information (PI) approved by the South African Health Products Regulatory Authority. S4 ELIGARD® Registration number: A39/26/649. Composition: One syringe contains the ATRIGEL® Delivery System, and the other contains lyophilised leuprolide acetate and is designed to deliver 22,5 mg leuprolide acetate at the time of subcutaneous injection. S4 ELIGARD® Registration number: A39/26/651. Composition: One syringe contains the ATRIGEL® Delivery System, and the other contains lyophilised leuprolide acetate and is designed to deliver 45 mg leuprolide acetate at the time of subcutaneous injection. References: 1. South African Approved Professional Information (PI). February 2014. 2. Schulman C. et al. BJU Int 2007;100(Suppl. 1):1-5. 3. Crawford DE et al. Prostate Cancer Prostatic Dis. 2019 Mar; 22(1):24-38. Applicant: Key Oncologics (Pty) Ltd Reg. No. 95/013825/07 39 11th Avenue, Houghton Estate, Johannesburg, 2198, South Africa Tel: +27 11 483 0060/5, Fax: +27 11 728 5060 Email: key@icon.co.za www.keyoncologics.co.za 11/2022 20885T
RkJQdWJsaXNoZXIy NTIyOTQ=